The Longevity Reality Radar

Lithocholic acid (CR mimetic)

Lithocholic acid (LCA) — a calorie-restriction mimetic. Aging itself. Reviewed Oct 2026.

Two Nature papers show a bile acid reproducing calorie-restriction effects in mice, worms and flies. There is no human data, and the same molecule is a standard way to induce liver injury in rodents.

Stage
Preclinical, animals only
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
D
animals only, no human data
Animal or lab only, single pilot, or case reports. How grades work.

What it is

A secondary bile acid. Your liver makes primary bile acids from cholesterol; gut bacteria carrying 7α-dehydroxylase convert the fraction that escapes reabsorption into LCA in the colon. Two Nature papers in 2025 reported that LCA accumulates in calorie-restricted mice and that giving LCA alone reproduces several effects of calorie restriction — without cutting food. The proposed route is a TULP3–sirtuin–v-ATPase–AMPK pathway, i.e. LCA binds TULP3, sirtuins deacetylate the v-ATPase V1E1 subunit, and AMPK switches on.

The evidence

Qu et al., Nature 2025 (doi 10.1038/s41586-024-08329-5): LCA activated AMPK, improved muscle regeneration and restored grip strength and running capacity in mice, and extended lifespan and healthspan in C. elegans and Drosophila. AMPK knockout abolished every effect. Companion paper (doi 10.1038/s41586-024-08348-2) mapped the TULP3 mechanism. What is missing matters more: no human trial, no human dosing, and in mice LCA extended healthspan without a reported lifespan extension — the lifespan results are in worms and flies, which cannot even synthesise LCA. Against it: LCA is the most hepatotoxic of the bile acids and is routinely used to induce cholestatic liver injury in rodents (Mol Med Rep 2020, PMID 32626965), and secondary bile acids are implicated in colon pathology (Acta Cir Bras 2015, PMID 26465107). A longevity molecule that is also a standard liver-toxicity model is not a supplement candidate yet. Also unproven: the popular claim that intermittent fasting, cyclic ketosis or “liver support” measurably raise your own LCA and thereby deliver calorie-restriction benefits. No human study has shown that chain. Note on route: the animal effects came from administered LCA at controlled doses, not from coaxing the gut microbiome into making more of it. Those are different interventions and only the first one was tested.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Aging itself

All 17 in Aging itself.

  • Rapamycin for longevityGrade C, strong animal data. Approved drug, off-label use.Extends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
  • Acarbose for longevityGrade C, strong animal data. Approved drug, off-label use.One of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
  • VO₂max and strength for longevityGrade B, large cohorts. Established.In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
  • RentosertibGrade C, post-hoc biomarker. Phase 3, for lung fibrosis.Six aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
  • Senolytics (dasatinib, quercetin, fisetin)Grade C, small human studies. Phase 1/2.Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
  • Partial epigenetic reprogramming (ER-100)Grade D, animal data only. Phase 1, in the eye.A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.